X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (64) 64
humans (62) 62
male (47) 47
female (38) 38
aged (37) 37
urology & nephrology (36) 36
middle aged (34) 34
adult (26) 26
renal cell carcinoma (24) 24
aged, 80 and over (16) 16
cancer (15) 15
kidney neoplasms - pathology (13) 13
oncology (13) 13
kidney neoplasms - surgery (12) 12
urology (12) 12
prognosis (11) 11
treatment outcome (10) 10
kidney (9) 9
nephrectomy (9) 9
surgery (9) 9
carcinoma (8) 8
metastasis (8) 8
neoplasm staging (8) 8
carcinoma, renal cell (7) 7
japan (7) 7
renal dialysis (7) 7
retrospective studies (7) 7
adolescent (6) 6
analysis (6) 6
carcinoma, renal cell - drug therapy (6) 6
carcinoma, renal cell - genetics (6) 6
carcinoma, renal cell - pathology (6) 6
carcinoma, renal cell - surgery (6) 6
kidney neoplasms - genetics (6) 6
survival (6) 6
time factors (6) 6
tomography, x-ray computed (6) 6
tumors (6) 6
diagnosis, differential (5) 5
disease-free survival (5) 5
expression (5) 5
kidney failure, chronic - complications (5) 5
kidney neoplasms - diagnosis (5) 5
kidney neoplasms - drug therapy (5) 5
therapy (5) 5
abridged index medicus (4) 4
carcinoma, renal cell - blood (4) 4
carcinoma, renal cell - diagnosis (4) 4
carcinoma, renal cell - immunology (4) 4
carcinoma, renal cell - secondary (4) 4
care and treatment (4) 4
diagnosis (4) 4
hemodialysis (4) 4
immunohistochemistry (4) 4
incidence (4) 4
kaplan-meier estimate (4) 4
kidney - metabolism (4) 4
kidney - pathology (4) 4
kidney failure, chronic - therapy (4) 4
kidney neoplasms - blood (4) 4
kidney neoplasms - complications (4) 4
kidney neoplasms - epidemiology (4) 4
kidney neoplasms - immunology (4) 4
kidney neoplasms - mortality (4) 4
letter to the editor (4) 4
lymph node excision (4) 4
magnetic resonance imaging (4) 4
neoplasm invasiveness (4) 4
nephrectomy - methods (4) 4
nephron-sparing surgery (4) 4
radical cystectomy (4) 4
sunitinib (4) 4
survival rate (4) 4
ureteral neoplasms - pathology (4) 4
urinary bladder neoplasms - pathology (4) 4
antineoplastic agents - therapeutic use (3) 3
biomarkers, tumor - blood (3) 3
bladder tumor (3) 3
carcinoma, renal cell - diagnostic imaging (3) 3
carcinoma, renal cell - epidemiology (3) 3
case report (3) 3
combined modality therapy (3) 3
connexins - genetics (3) 3
development and progression (3) 3
functional residual capacity (3) 3
growth (3) 3
hypertension (3) 3
immunology (3) 3
immunotherapy (3) 3
interleukin-8 (3) 3
japan - epidemiology (3) 3
kidney diseases, cystic - metabolism (3) 3
kidney failure, chronic - surgery (3) 3
kidney neoplasms - diagnostic imaging (3) 3
lymph nodes - pathology (3) 3
medical research (3) 3
medicine, experimental (3) 3
multicenter (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
original paper (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Japanese Journal of Clinical Urology, ISSN 0385-2393, 2016, Volume 70, Issue 12, pp. 956 - 961
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 4/2007, Volume 56, Issue 4, pp. 469 - 476
Journal Article
Cancer Science, ISSN 1347-9032, 09/2017, Volume 108, Issue 9, pp. 1858 - 1863
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2011, Volume 47, Issue 17, pp. 2592 - 2602
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 12/2007, Volume 35, Issue 12, pp. 2166 - 2176
Olmesartan, a novel angiotensin II AT1-receptor antagonist, is excreted into both bile and urine, with minimal metabolism. Because olmesartan is a hydrophilic... 
PHARMACOKINETICS | INVOLVEMENT | PHARMACOLOGY & PHARMACY | RESISTANCE-ASSOCIATED PROTEIN-4 | ORGANIC ANION TRANSPORTERS | EXCRETION | IDENTIFICATION | MEDOXOMIL | EXPRESSION | OATP1B1 | BLOCKER | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Humans | ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism | Membrane Transport Proteins - drug effects | Hepatocytes - metabolism | Imidazoles - pharmacokinetics | Neoplasm Proteins - metabolism | Angiotensin II Type 1 Receptor Blockers - pharmacokinetics | Sincalide - metabolism | Angiotensin II Type 1 Receptor Blockers - metabolism | Organic Anion Transporters - metabolism | Prodrugs - metabolism | Tetrazoles - metabolism | Dose-Response Relationship, Drug | Kidney - metabolism | Protein Isoforms - metabolism | Transfection | Liver - drug effects | Membrane Transport Proteins - genetics | Organic Anion Transporters, Sodium-Independent - metabolism | Adenosine Triphosphate - metabolism | ATP-Binding Cassette Transporters - metabolism | Female | Membrane Transport Proteins - metabolism | Hepatocytes - drug effects | Solute Carrier Organic Anion Transporter Family Member 1B3 | Imidazoles - metabolism | Olmesartan Medoxomil | Cell Line | Liver - metabolism | Probenecid - pharmacology | Penicillin G - pharmacology | Mice, Knockout | p-Aminohippuric Acid - pharmacology | Animals | Estrone - analogs & derivatives | Multidrug Resistance-Associated Proteins - deficiency | Prodrugs - pharmacokinetics | Estrone - metabolism | Dogs | Protein Binding | ATP Binding Cassette Transporter, Sub-Family B | Mice | Kinetics | In Vitro Techniques | Solute Carrier Organic Anion Transporter Family Member 1b1 | Multidrug Resistance-Associated Proteins - metabolism | Tetrazoles - pharmacokinetics | Index Medicus
Journal Article
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 03/2015, Volume 45, Issue 3, pp. 274 - 280
Journal Article
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 05/2011, Volume 41, Issue 5, pp. 647 - 655
Objective: We investigated the safety and feasibility of sorafenib in patients with end-stage renal disease undergoing hemodialysis by examining the influence... 
Pharmacokinetics | Adverse drug events | Hemodialysis | Renal cell carcinoma | Sorafenib | RISK-FACTORS | sorafenib | SAFETY | PHASE-II | adverse drug events | renal cell carcinoma | THERAPY | DIALYSIS PATIENTS | ONCOLOGY | DISEASE | hemodialysis | pharmacokinetics | SUNITINIB | REFRACTORY SOLID TUMORS | JAPANESE PATIENTS | INHIBITOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Benzenesulfonates - adverse effects | Feasibility Studies | Benzenesulfonates - pharmacokinetics | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Benzenesulfonates - blood | Antineoplastic Agents - pharmacokinetics | Hemoglobins - drug effects | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms - complications | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Erythropoietin - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Hemoglobins - metabolism | Treatment Outcome | Hematinics - administration & dosage | Kidney Failure, Chronic - therapy | Disease-Free Survival | Pyridines - blood | Sample Size | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Antineoplastic Agents - blood | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Kidney Failure, Chronic - etiology | Renal Dialysis | Index Medicus
Journal Article